Vivacelle Bio Inc.
Kansas City, MO
- UEI
- DFXZMMZ9BB21
- CAGE
- 6PQ21
- Primary NAICS
- 541713 Research and Development in Nanotechnology
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 2300 Main St #900, Kansas City, MO 64108, USA
- Website
- vivacellebio.com
- Founded
- 2013
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of VBI-1 as a novel treatment protocol for outpatient cardiac arrest - project summary cardiac arrest (CA)… | National Heart Lung and Blood Institute | $559,138 | |
| Strategy for warfighter survival after exsanguination | Defense Health Agency | $737,639 | |
| Nitric oxide redistribution by a phospholipid nanoparticle colloid to treat septic shock. - project summary septic shock… | National Institute of General Medical Sciences | $755,649 |
About Vivacelle Bio Inc.
Vivacelle Bio Inc. is a minority-owned, for-profit corporate entity registered in SAM.gov that specializes in developing advanced medical technologies, with a particular focus on innovative pharmaceutical and medical interventions for critical care scenarios. The company appears to be a biotechnology research organization concentrating on developing specialized colloidal nanoparticle formulations designed to address complex medical challenges in emergency and critical care settings, such as cardiac arrest, hemorrhagic shock, and septic shock.
Through its federal grant awards, Vivacelle Bio Inc. has secured significant research funding from multiple federal agencies to develop its proprietary VBI-1 treatment protocol, a unique phospholipid nanoparticle suspension. The company has received project grants from civilian agencies like the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of General Medical Sciences, as well as defense-related funding from the Defense Health Agency. These grants, totaling over $559,138, support research into novel medical interventions, including developing treatments for outpatient cardiac arrest, strategies for warfighter survival after exsanguination, and potential solutions for managing septic shock. The research focuses on creating advanced resuscitation fluids that can modulate nitric oxide, carry oxygen, reduce inflammatory responses, and improve patient outcomes in critical medical scenarios. Each grant represents a phase of research aimed at preclinical validation, demonstrating the potential of VBI-1 as an innovative medical intervention across different life-threatening conditions.
Quick answers
What is Vivacelle Bio Inc.'s UEI?
Vivacelle Bio Inc.'s Unique Entity ID (UEI) in SAM.gov is DFXZMMZ9BB21.
What is Vivacelle Bio Inc.'s CAGE code?
Vivacelle Bio Inc.'s CAGE code is 6PQ21.
What is Vivacelle Bio Inc.'s primary NAICS code?
Vivacelle Bio Inc.'s primary NAICS code is 541713 (Research and Development in Nanotechnology).
Where is Vivacelle Bio Inc. located?
Vivacelle Bio Inc.'s physical address in SAM.gov is 2300 Main St #900, Kansas City, MO 64108, USA.
Is Vivacelle Bio Inc. registered in SAM.gov?
Yes. Vivacelle Bio Inc.'s SAM.gov registration is active through June 30, 2027.
What is Vivacelle Bio Inc.'s most recent federal award?
Vivacelle Bio Inc.'s most recent federal grant award is Development of VBI-1 as a novel treatment protocol for outpatient cardiac arrest - project summary cardiac arrest (CA)… (R41HL174360), from National Heart Lung and Blood Institute, on September 1, 2024.
On GovTribe
See Vivacelle Bio Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors